EFFICACY AND SAFETY OF SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO LBEC0101 (ETANERCEPT BIOSIMILAR) COMPARED WITH CONTINUING LBEC0101 IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：3

作者：

Song, Y. W. ^{[1
]}

Matsuno, H. ^{[2
,3
]}

Park, M. -C. ^{[4
]}

Tomomitsu, M. ^{[5
]}

Shin, S. ^{[6
]}

Lee, J. ^{[6
]}

机构：

[1] Seoul Natl Univ Hosp, Seoul, South Korea

[2] Tokyo Med Univ, Tokyo, Japan

[3] Matsuno Clin Rheumat Dis, Toyama, Japan

[4] Yonsei Univ, Div Rheumatol, Coll Med, Seoul, South Korea

[5] Mochida Pharmaceut Co Ltd, Tokyo, Japan

[6] LG CHEM, Seoul, South Korea

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷

关键词：

D O I：

10.1136/annrheumdis-2018-eular.1316

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0456

引用

页码：1389 / 1390

页数：3

共 50 条

[11] LONG-TERM SAFETY AND EFFICACY OF SB4 (ETANERCEPT BIOSIMILAR) IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON BETWEEN CONTINUING SB4 AND SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO SB4
Emery, P.
Vencovsky, J.
Sylwestrzak, A.
Leszczynski, P.
Porawska, W.
Stasiuk, B.
Hilt, J.
Mosterova, Z.
Cheong, S. Y.
Ghil, J.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 236 - 236
[12] Efficacy, safety and immunogenicity of the biosimilar etanercept compared to the reference formulation original etanercept in patients with rheumatoid arthritis: An open-label, randomized, comparative, multicenter study
Pekhenko, Valentyna
Udovitskiy, Vlad
Barbukho, Olena
MEDICINE, 2024, 103 (30)
[13] The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis
Hansen, KE
Hildebrand, JP
Genovese, MC
Cush, JJ
Patel, S
Cooley, DA
Cohen, SB
Gangnon, RE
Schiff, MH
JOURNAL OF RHEUMATOLOGY, 2004, 31 (06) : 1098 - 1102
[14] The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
Hansen, KE
Cush, JJ
Patel, S
Genovese, MC
Schiff, M
ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S538 - S538
[15] Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
Emery, Paul
Vencovsky, Jiri
Sylwestrzak, Anna
Leszczynski, Piotr
Porawska, Wieslawa
Stasiuk, Barbara
Hilt, Joanna
Mosterova, Zdenka
Cheong, Yeon
Ghil, Jeehoon
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (12) : 1986 - 1991
[16] Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data
Atzeni, Fabiola
Gerratana, Elisabetta
Bongiovanni, Sara
Talotta, Rossella
Miceli, Gianfranco
Salaffi, Fausto
Sarzi-Puttini, Piercarlo
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 344 - 349
[17] AUDIT OF THE CLINICAL EFFICACY AND SAFETY OF ETANERCEPT BIOSIMILAR TO ITS REFERENCE PRODUCT IN PATIENTS WITH INFLAMMATORY ARTHRITIS: EXPERIENCE FROM A DISTRICT GENERAL HOSPITAL IN THE UNITED KINGDOM
Ma, J.
Petford, S.
Jones, L.
Douglas, K.
John, H.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1386 - 1386
[18] AUDIT OF THE CLINICAL EFFICACY AND SAFETY OF ETANERCEPT BIOSIMILAR TO ITS REFERENCE PRODUCT IN PATIENTS WITH INFLAMMATORY ARTHRITIS: EXPERIENCE FROM A DISTRICT GENERAL HOSPITAL IN THE UNITED KINGDOM
Ma, Jianfei
Petford, Sharon
Jones, Lisa
Douglas, Karen
John, Holly
RHEUMATOLOGY, 2018, 57
[19] A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
Yamanaka, Hisashi
Kamatani, Naoyuki
Tanaka, Yoshiya
Hibino, Toshihiko
Drescher, Edit
Sanchez-Burson, Juan
Rettenbacher, Manfred
Bhatia, Girish
Gadve, Snehal
Shah, Chirag
Bakhle, Dhananjay
RHEUMATOLOGY AND THERAPY, 2020, 7 (01) : 149 - 163
[20] A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis
Hisashi Yamanaka
Naoyuki Kamatani
Yoshiya Tanaka
Toshihiko Hibino
Edit Drescher
Juan Sánchez-Bursón
Manfred Rettenbacher
Girish Bhatia
Snehal Gadve
Chirag Shah
Dhananjay Bakhle
Rheumatology and Therapy, 2020, 7 : 149 - 163

← 1 2 3 4 5 →